Organization
European Institute of Oncology
12 clinical trials
16 abstracts
6 posters
Abstract
Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).Org: Medical Oncology, Yale School of Medicine, Yale Cancer Center, Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
Evaluation of PAM50 intrinsic subtypes and risk of recurrence (ROR) scores in premenopausal women with early-stage HR+ breast cancer: A secondary analysis of the SOFT trial.Org: University of Chicago, European Institute of Oncology, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Peter MacCallum Cancer Centre, Melbourne, Australia, International Breast Cancer Study Group,
Abstract
Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome.Org: Niguarda Cancer Center, Laboratory of Experimental Hematology, Clinic of Hematology, Ente Ospedaliero Cantonale, Universita’ della Svizzera italiana,
Abstract
BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial.Org: Royal Marsden Hospital NHS Foundation Trust, Medical Oncology Service, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), National and Kapodistrian University of Athens,
Abstract
Comparing 18F-FDG positron emission tomography (PET) and breast magnetic resonance imaging (MRI) to predict pathological complete response (pCR) and 3-year invasive disease-free survival (3-y iDFS) in patients (pts) with HER2+ early breast cancer (EBC): An unplanned exploratory analysis of PHERGain trial.Org: International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Medica Scientia Innovation Research (MEDSIR) - Oncoclínicas&Co, Jersey City (New Jersey, USA),
Abstract
Impact of hormone receptor status and tumor subtypes on clinical behavior and outcomes of breast cancer in young BRCA carriers.Org: Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genoa, Genoa, Italy, Academic Trials Promoting Team, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Brussels, Belgium, U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genova, Italy, Department of Medical Oncology, Universite Paris Cité, Institut Curie, Paris, France, Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea,
Abstract
Triplet combination treatments with pembrolizumab (pembro) for anti–PD-(L)1–refractory advanced melanoma: Preliminary results of the phase 1/2 KEYMAKER-U02A study.Org: University Hospital Zurich, Aix-Marseille University CHU Timone, Hôpital de la Timone, Department of Cancer Medicine, Gustave Roussy Cancer Centre, Gustave Roussy Cancer Campus,
Abstract
Comprehensive analysis of TROP2, PD-L1, stromal (s)TILs, and HER2 expression patterns in patients (pts) with metastatic HR+HER2- breast cancer.Org: Dana-Farber Cancer Institute, University of Milan and European Institute of Oncology, IRCCS, Brigham and Women's Hospital, University of Milano, European Institute of Oncology, Division of Early Drug Development, European Institute of Oncology,
Abstract
INAVO122: A phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients (pts) with PIK3CA-mutated, HER2-positive advanced breast cancer (HER2+ aBC).Org: Genentech, Product Development Data Science, F. Hoffmann-La Roche Ltd., F. Hoffmann-La Roche Ltd, Roche Products Ltd., Product Development Oncology, F. Hoffmann-La Roche Ltd.,
Clinical trial
Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion: a Randomized Phase II Biomarker Trial in Subjects at Increased RiskStatus: Not yet recruiting, Estimated PCD: 2025-07-31
Abstract
Unfavourable carcinoma of unknown primary (CUP) with gastrointestinal profile: A retrospective study.Org: Istituto Europeo di Oncologia IRCCS, Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, European Institute of Oncology IRCCS, University of Milano, European Institute of Oncology, Division of Early Drug Development, European Institute of Oncology (IEO),
Clinical trial
POSITive: Prospective Observational Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapiesStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer: a Feasibility Phase II TrialStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
A Phase II, Multicentric, Open Label, Non-randomized, Interventional Study of Pembrolizumab in Combination With Electrochemotherapy in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral MetastasesStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
The HOT Study: Hormone Replacement Therapy Opposed by Low Dose Tamoxifen. A Phase III Trial of Breast Cancer Prevention With Low Dose Tamoxifen in HRT Users.Status: Active (not recruiting), Estimated PCD: 2018-12-01
Clinical trial
Radioablation +/- Hormonotherapy for Prostate Cancer Oligorecurrences (RADIOSA Trial): Potential of Imaging and BiologyStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
Nonmyeloablative Hematopoietic Stem Cell Transplantation (SCT) for High-Risk Hematologic Malignancies With Related, HLA-Haploidentical Donors: A Phase II Trial of Immunosuppression With Cyclophosphamide Administered Before and After SCTStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase II Study of Metronomic Oral Chemotherapy With Cyclophosphamide Plus Capecitabine and Vinorelbine in Metastatic Breast Cancer PatientsStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Combination of Pembrolizumab With Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer (PERICLES): A Phase II StudyStatus: Not yet recruiting, Estimated PCD: 2023-07-01
Clinical trial
ICOS-ONE - Prevention of Anthracycline-induced Cardiotoxicity: a Multicentre Randomized Trial Comparing Two Therapeutic Strategies.Status: Active (not recruiting), Estimated PCD: 2019-12-01
Clinical trial
Accelerated Modulated Fractionation (SIB-IMRT) for the Treatment of Locally Advanced Squamous Cell Carcinoma From Head and Neck DistrictStatus: Recruiting, Estimated PCD: 2018-12-01
Abstract
Total neoadjuvant treatment without surgery for locally advanced rectal cancer: Prospective study to assess tumor response, circulating genetic, and epigenetic biomarkers, and stromal transcriptome to interpret clinical outcome (NO-CUT trial).Org: Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, University of Milano, European Institute of Oncology, Division of Early Drug Development, European Institute of Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
Immune checkpoint inhibitor in high-risk oral potentially malignant disorders (IMPEDE study): An interim analysis on safety.Org: University of Brescia, ASST Spedali Civili - Brescia, Angelo Nocivelli Institute of Molecular Medicine, University of Brescia and ASST-Spedali Civili, ASST-Spedali Civili of Brescia,
Abstract
HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer.Org: Sarah Cannon Research Institute at Tennessee Oncology, PLLC, Hospital General Universitario Gregorio Marañón, Mayo Clinic, European Institute of Oncology, Yonsei Cancer Center, Yonsei University Health System,
Abstract
A phase II study of tinostamustine in patients (pts) with advanced solid tumours.Org: Mary Crowley Cancer Research, University of Michigan, European Institute of Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain,
Abstract
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.Org: Lungen Clinic Grosshansdorf, Airway Research Center North (ARCN), German Center of Lung Research (DZL), Grosshansdorf, Servicio de Oncología Médica, Hospital Universitario de Jaén, European Institute of Oncology,
Clinical trial
A Phase II, Multicentric, Open Label, Non-randomized, Interventional Study of Pembrolizumab in Combination With Electrochemotherapy in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral MetastasesStatus: Withdrawn, Estimated PCD: 2023-12-01
Abstract
Clinical and radiological criteria for candidate patients with small bowel neuroendocrine neoplasms (SB-NEN) for minimally invasive surgery: A single-centre experience.Org: Istituto Europeo di Oncologia IRCCS, European Institute of Oncology, IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, European Institute of Oncology (IEO) IRCCS,